Contact ThinWorks if you would like to try BPC-157 peptide therapy
Most of centella's magic comes from the four big compounds (Asiaticoside, Madecassoside, Asiatic Acid, and Madecassic Acid)
As shown in Figures 7 AC, KA treatment significantly increased the release of MDA and Fe 2+ , whereas it decreased GSH
5-Amino-1MQ is a small-molecule NNMT inhibitor studied for its role in cellular metabolism and methylation-related pathways
Disclosures: Takumi Kawaguchi: ASKA Pharmaceutical Co., Ltd.: Speaking and Teaching, Taisho Pharmaceutical Co., Ltd.: Speaking and Teaching, Kowa Company, Ltd.: Speaking and Teaching, AbbVie GK.: Speaking and Teaching, Eisai Co., Ltd.: Speaking and Teaching, Novo Nordisk Pharma Ltd.: Speaking and Teaching, Janssen Pharmaceutical K.K.: Speaking and Teaching, Janssen Pharmaceutical K.K.: Speaking and Teaching, Otsuka Pharmaceutical Co., Ltd.: Speaking and Teaching, EA Pharma Co.,Ltd.: Speaking and Teaching, Kenta Murotani: Nothing to Disclose, Hiromitsu Kajiyama: Nothing to Disclose, Hitoshi Obara: Nothing to Disclose, Hironori Yamaguchi: Nothing to Disclose, Yuko Toyofuku: Nothing to Disclose, Fumi Kaneko: Nothing to Disclose, Yutaka Seino: Nothing to Disclose, Saeko Uchida: Nothing to Disclose 1602 CHANGING PRESCRIPTION PATTERN OF ANTI-DIABETIC MEDICATIONS AND IMPROVEMENT IN GLYCEMIC CONTROL IN PATIENTS WITH T2DM, WITH AND WITHOUT CIRRHOSIS: A TERRITORY-WIDE COHORT STUDY IN HONG KONG FROM 2000-2023 Mary Yue Wang 1 Sherlot Juan Song 1 Grace Lai-Hung Wong 1 Vincent Wong 1 Terry Cheuk-Fung Yip 1 , 1 The Chinese University of Hong Kong Background: We aimed to compare the secular trends of glycemic control and anti-diabetic medication use in patients with type 2 diabetes mellitus (T2DM), with and without cirrhosis in a retrospective cohort in Hong Kong
